About Ambagon
Ambagon is a company based in San Francisco (United States) founded in 2020 by Luc Brunsveld, Christian Ottmann, and Michelle Arkin.. Ambagon has raised $108 million across 3 funding rounds from investors including AbbVie, Citadel and RA Capital. Ambagon offers products and services including Molecular Glue Platform. Ambagon operates in a competitive market with competitors including Daré Bioscience, Olema Oncology, Atossa Therapeutics, Puma Biotechnology and Minerva Biotechnologies, among others.
- Headquarter San Francisco, United States
- Founders Luc Brunsveld, Christian Ottmann, Michelle Arkin
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$108 M (USD)
in 3 rounds
-
Latest Funding Round
$5 M (USD), Series A
Jan 24, 2025
-
Investors
AbbVie
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ambagon
Ambagon offers a comprehensive portfolio of products and services, including Molecular Glue Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing medicines targeting undruggable proteins.
Unlock access to complete
Unlock access to complete
Funding Insights of Ambagon
Ambagon has successfully raised a total of $108M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $5.0M
-
First Round
First Round
(24 Nov 2021)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series A - Ambagon | Valuation |
investors |
|
| Jan, 2022 | Amount | Series A - Ambagon | Valuation | Nextech Invest | |
| Nov, 2021 | Amount | Seed - Ambagon | Valuation | RA Capital Management , Inkef Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ambagon
Ambagon has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, Citadel and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Early & late stage VC firm investing primarily in Netherlands
|
Founded Year | Domain | Location | |
|
Investments in life science startups are made by Mission BioCapital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ambagon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ambagon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ambagon Comparisons
Competitors of Ambagon
Ambagon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Olema Oncology, Atossa Therapeutics, Puma Biotechnology and Minerva Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| domain | founded_year | HQ Location |
Drug therapeutics for breast cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for breast cancer treatment and prevention are developed.
|
|
| domain | founded_year | HQ Location |
Tyrosine kinase inhibitors for breast cancer are developed.
|
|
| domain | founded_year | HQ Location |
Cell therapy and antibodies are developed to treat cancer.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Ambagon
When was Ambagon founded?
Ambagon was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Ambagon located?
Ambagon is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Ambagon?
Scott Clarke is the current CEO of Ambagon.
Is Ambagon a funded company?
Ambagon is a funded company, having raised a total of $108M across 3 funding rounds to date. The company's 1st funding round was a Seed of $18M, raised on Nov 24, 2021.
What does Ambagon do?
Ambagon was founded in 2020 and is headquartered in San Francisco, United States. Small-molecule therapeutics targeting cancer are developed within the biotechnology sector. Focus is placed on drugs that stabilize interactions between oncogenic proteins and the 14-3-3 class of adaptor proteins. A novel method is employed to inhibit oncogenic transcription factors in cancers driven by specific genetic alterations. Operations center on advancing these therapeutics through research and development.
Who are the top competitors of Ambagon?
Ambagon's top competitors include Atossa Therapeutics, Daré Bioscience and Puma Biotechnology.
What products or services does Ambagon offer?
Ambagon offers Molecular Glue Platform.
Who are Ambagon's investors?
Ambagon has 8 investors. Key investors include AbbVie, Citadel, RA Capital, Nextech Invest, and Inkef Capital.